Pioneering the First-in-Class in vivo Protein Engineering Platform to
Transform
the Treatment
PARADIGM
About Vironexis
Bringing the Full Potential of T-Cell Immunotherapy to Patients
T-cell immunotherapies have transformed care for select cancers, but CAR-T, bispecific antibodies, and antibody-drug conjugates each carry significant trade-offs — complex manufacturing, narrow safety windows, repeat dosing, and limited durability — that prevent the modality from reaching the patients who need it most.
Vironexis is a clinical-stage biotechnology company building the world’s first in vivo protein engineering platform. Our proprietary TransJoin™ technology uses non-integrating AAV vectors to instruct the liver to continuously secrete a T cell engager from a single IV dose — eliminating ex vivo manufacturing, lymphodepletion, and the high-dose toxicities that limit existing T cell therapies.
World’s first in vivo protein engineering platform delivering vectorized T-cell engagers in a single IV dose
With our TransJoin™ in vivo protein engineering platform, a single intravenous dose instructs the patient’s liver to produce a bispecific T-cell engager continuously and at steady state — without leukapheresis, lymphodepletion, or repeat infusion.
The result is durable, T-cell-mediated tumor killing in an off-the-shelf format, with the safety, scalability, and patient accessibility that today’s CAR-T, bispecific, and ADC therapies cannot match. A single injection should produce sustained, steady-state therapeutic protein expression for months to years.
About Vironexis
Pipeline
Our plug-and-play platform has advanced 10+ candidates across hematologic malignancies, solid tumors, and immune disorders. VNX-101 (CD19+ leukemias and lymphomas) and VNX-202 (HER2+ cancers) are in Phase 1/2 clinical trials.
Oncology Part 1 – Blood Based Cancer
VNX-101
VNX-102
VNX-103
Oncology Part 2 – Solid Tumors
VNX-201
VNX-202
VNX-204
VNX-205
VNX-206
VNX-207
Autoimmune Programs
VNX-101-2
VETERANS
OF AAV GENE THERAPY AND ONCOLOGY
Our team brings together the people who built and commercialized first-generation AAV gene therapies — including Zolgensma® — with the clinicians, operators, and drug developers translating that experience into a new modality. We’ve combined that know-how to redefine patient treatment with the world’s first in vivo protein engineering platform.